News

Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with…
Read More...

Innovent Biologics, Inc. and The University of Texas MD Anderson Cancer Center announced a strategic collaboration agreement to co-develop TYVYT (sintilimab injection), Innovent's…
Read More...

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment…
Read More...

Deciphera Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has approved QINLOCK (ripretinib) for the treatment of adult patients with advanced…
Read More...

Takeda China announced that ADCETRIS (brentuximab vedotin) has been officially approved by China’s National Medical Products Administration (NMPA) for use in adult patients with…
Read More...

Boehringer Ingelheim announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies…
Read More...

Colorcon, a world leader in the development and supply of film coating systems and excipients, today announces SoteriaRx. This new platform of innovative on-dose technologies and…
Read More...

Recursion announced it has entered into a global licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to gain rights to TAK-733, a clinical-stage MEK inhibitor, and…
Read More...

Neuraptive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its franchise therapeutic product, NTX-001, in the…
Read More...

Evonik announced the successful commissioning of an advanced biomaterials facility in Birmingham, USA that will support the increasing global market demand for the use of RESOMER…
Read More...

Catalent announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19. Under the terms of the agreement, Catalent will develop a…
Read More...

Boehringer Ingelheim and CDR-Life announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic…
Read More...

BioMed X, an independent research institute that identifies big biomedical research challenges and provides innovative solutions by combining global crowdsourcing with local incubation,…
Read More...

Cipla Limited announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine…
Read More...

CytoAgents announced that it has been awarded a National Institutes of Health (NIH) grant to accelerate the development of its lead drug candidate, GP1681, an investigational new drug…
Read More...

Skyhawk Therapeutics, Inc. announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and…
Read More...

Legend Biotech Corporation announced that Legend and Noile-Immune Biotech, Inc. have entered into a license agreement whereby Legend will have the right to develop CAR-T and/or TCR-T…
Read More...

Glenmark Pharmaceuticals, a research-led integrated global pharmaceutical company, has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received…
Read More...

Seattle Genetics, Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and…
Read More...